Highest-materiality recent filing
Cue Biopharma Q2 net loss $153M, revenue $7.9M, $50M PIPE
Q2 revenue $7.9M vs $3.0M YoY; net loss $153.1M vs $8.5M, driven by one-time charges.
Cue Biopharma appoints James Ahlers as CFO effective July 30, 2026
James Ahlers appointed CFO of Cue Biopharma effective July 30, 2026.
Cue Biopharma raises $50M in private placement led by Cormorant and Columbia Threadneedle
Gross proceeds of $50M from sale of 1,418,071 shares at $33.21/share and pre-funded warrants for 87,500 shares at $33.209.
Resignations of directors Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen effective May 29, 2026.
Cue Biopharma Q1 net loss $5.2M; appoints new CEO, $30M private placement, CUE-221 license
Net loss $5.2M ($1.08 EPS) vs $12.3M loss in Q1 2025; revenue $5.7M from Boehringer collaboration.
Cue Biopharma licenses ex-China rights to anti-IgE mAb Ascendant-221; raises $30M; appoints new CEO
License with Ascendant Health Sciences: $15M upfront, up to $676.5M milestones, tiered high-single-to-low-double-digit royalties on ex-China sales.
Cue Biopharma files 1-for-30 reverse stock split to maintain Nasdaq listing
1-for-30 reverse stock split effective 5:00 PM ET on April 23, 2026; no fractional shares, cash in lieu.
Cue Biopharma achieves preclinical milestone with Boehringer Ingelheim; $7.5M payment due May 2026
Boehringer Ingelheim approved selection of first compound for lead optimization under April 2025 collaboration.
Cue Biopharma CEO Usman Azam resigns; Lucinda Warren named Interim CEO
Usman Azam resigned as President, CEO and Board member effective March 26, 2026.
Cue Biopharma reports Q4 net income of $1.6M on $21.9M collab revenue from ImmunoScape; cash $27.1M
Net income $1.585M ($0.01 EPS) in Q4 2025 vs net loss $9.496M in Q4 2024; full-year net loss $26.6M vs $40.7M.
Cue Biopharma raises ~$10M in dilutive public offering; cash runway through Q1 2027
Gross proceeds ~$10M from 35.7M shares/pre-funded warrants and 17.9M warrants at $0.28 combined offering price.
Cue Biopharma CMO Matteo Levisetti to depart Nov 28; gets $556,838 severance
Chief Medical Officer Matteo Levisetti will terminate employment effective November 28, 2025.
Cue Biopharma licenses CUE-100 series to ImmunoScape; receives $15M cash and 40% equity
Collaboration with ImmunoScape to develop 'Seed-and-Boost' TCR-T cell therapy for solid tumors using CUE-100 series.
Cue Biopharma appoints Usman Azam as CEO, succeeding Daniel Passeri who transitions to advisor
Usman Azam appointed President and CEO effective Sept 29, 2025; succeeds Daniel Passeri who retires and becomes strategic advisor.
Cue Biopharma Q2 net loss $8.5M; BI deal with $12M upfront, $345M milestones
Net loss $8.5M ($0.09/share) vs $10.2M in Q2 2024; collaboration revenue $3.0M.
Cue Biopharma CFO resigns, elects Jill Broadfoot to board, increases authorized shares to 310M
CFO Kerri-Ann Millar resigns effective June 13, 2025; CEO Daniel Passeri will be interim principal financial and accounting officer.
Cue Biopharma Q1 net loss $12.3M; announces BI collaboration for CUE-501 and $20M capital raise
Net loss $12.3M ($0.17 EPS) vs $12.3M ($0.25) YoY; revenue $0.4M down from $1.7M.
Cue Biopharma prices $20M public offering; $13.1M cash; runway into Q2 2026
Pricing of 13.53M common shares + warrants at $0.79/unit; $20M gross proceeds.
Cue Biopharma inks collaboration with Boehringer Ingelheim for B cell depletion; $12M upfront
Upfront payment of $12M; eligible for up to $345M in success-based research, development, and commercial milestones.
Cue Biopharma Q4 2024 net loss narrows to $9.5M; cash at $22.5M; pipeline pivots to autoimmune
Net loss of $9.5M in Q4 2024 ($0.13/share) vs $13.4M in Q4 2023; full year net loss $40.7M.
Cue Biopharma Q3 net loss narrows to $8.7M; CUE-101 combo shows 46% ORR in HPV+ HNSCC
Net loss of $8.7M ($0.17 per share) vs $11.0M loss ($0.24) in Q3 2023; collaboration revenue rose to $3.3M.
Cue Biopharma prices $12M public offering of stock and warrants, extends cash runway into Q4 2025
10.6M shares of common stock and 2.9M common stock warrants offered at $0.50 per unit; pre-funded warrants for 12.4M shares at $0.499.
Cue Biopharma receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq notice on August 15, 2024 for failure to meet minimum bid price of $1.00 for 30 consecutive business days.
Cue Biopharma restructures, cuts workforce 25%, extends cash runway to mid-2025
Reduces workforce by ~25% across R&D and G&A; CEO Daniel Passeri takes 50% salary reduction, execs forgo 2023 bonuses.
Cue Biopharma reports Q1 2024 net loss $12.3M, cash $41M into Q1 2025
Collaboration revenue $1.7M vs $0.2M YoY; net loss $0.25/share vs $0.29.
Cue Biopharma raises $30M in PIPE financing; sells shares, pre-funded warrants, and warrants
Gross proceeds of $30M; net proceeds ~$28.2M after fees.
Cue Biopharma Director Cameron Gray Resigns from Board
Cameron Gray notified Cue Biopharma of his resignation as a Board member on June 16, 2022.
Cue Biopharma signs 4-year license for Boston office/lab space; monthly rent $200,700
Lease covers ~13,000 sq ft at 40 Guest Street, Boston; term April 15, 2022 to April 14, 2026.
Cue Biopharma enters $20M SVB loan facility with tranche A of $10M available immediately
Tranche A of $10M funded at closing; two additional tranches up to $5M each contingent on CUE-101 data and equity proceeds.
Cue Biopharma enters $80M at-the-market equity offering agreement with Jefferies
Company enters Open Market Sale Agreement with Jefferies LLC to sell up to $80M of common stock at-the-market.
On August 3, 2026, Cue Biopharma, Inc. (the “Company”) announced that the Company’s Board of Directors (the “Board”) appointed James Ahlers as the Company’s Chief Financial Officer, effective as of July 30, 2026 (the “Effective Date”).
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.
On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.
On June 1, 2026, the Board appointed Michael Meluzio as the Company’s Vice President, Principal Accounting Officer, to serve as the Company’s principal accounting officer, effective June 1, 2026.
On June 1, 2026, the Board appointed Sumita Ray, JD, as the Company’s Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026.
Mr. Sandercock will continue to serve as the Company’s Senior Vice President, Intellectual Property.
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
On April 27, 2026, the Board appointed Dr. Shao-Lee Lin as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of her commencement of employment with the Company, which began on April 30, 2026
On April 27, 2026, the Board appointed Dr. Shao-Lee Lin as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of her commencement of employment with the Company, which began on April 30, 2026
Max materiality 0.90 · Median 0.60 · Most common event other_material